Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 1/2022

01-03-2022 | Helicobacter Pylori | Case Report

A Case Study on Modeling the Time to Recurrence of Gastric Cancer Patients

Authors: Mesfin Esayas Lelisho, Adem Aregaw Seid, Digvijay Pandey

Published in: Journal of Gastrointestinal Cancer | Issue 1/2022

Login to get access

Abstract

Background

Gastric cancer is a malignant tumor of the stomach and it is one of the leading causes of death worldwide. The study aimed to model the time to first recurrence of gastric cancer patients at the Tikur Anbesa specialized hospital.

Methods

The data for this study were gastric cancer patients followed up from January 1, 2013 to February 29, 2020 at Tikur Anbesa Specialized Hospital, Oncology Center, Addis Ababa. We used Weibull, log-logistic and lognormal as baseline hazard functions with the gamma and the inverse Gaussian frailty distributions. Data analyzed with the statistical software R.

Results

The median recurrence time of the patients was about 23.96 months with a maximum recurrence time of 60.81 months, of which about 61.2% had first recurrences of gastric cancer. The clustering effect is significant in modeling the time to recurrence of gastric cancer. According to the result of the log-logistic inverse Gaussian frailty model, the sex of the patient, the tumor size, smoking habit, the treatment carried out, the vascular invasion, the stage of the disease, the helicobacter pylori infection and the histological type were the significant prognostic factors  at 5% level of significance.

Conclusion

Inverse Gaussian frailty model is the model that best describes the time to recurrence of the gastric cancer data set. Gender of the patients, tumor size, treatment taken, vascular invasion, disease stage, helicobacter pylori infection and histological type were the determining prognostic factors. This requires measures to improve patient health and prevent relapse based on significant risk factors, and particular attention should be paid to patients with such factors.
Literature
1.
go back to reference Rugge M, Fassan M, Graham DY. Epidemiology of gastric cancer. Gastric Cancer., Springer, Cham. 2015. pp. 23–34. Rugge M, Fassan M, Graham DY. Epidemiology of gastric cancer. Gastric Cancer., Springer, Cham. 2015. pp. 23–34.
2.
go back to reference WHO. The World Health Organization's fight against cancer: strategies that prevent, cure and care. World Health Organization. 2017. WHO. The World Health Organization's fight against cancer: strategies that prevent, cure and care. World Health Organization. 2017.
3.
go back to reference Freddie, et al. Bray, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries., CA: Cancer J Clin. 2018. pp. 394–424. Freddie, et al. Bray, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries., CA: Cancer J Clin. 2018. pp. 394–424.
4.
go back to reference Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors, J Clini Epidemiol. 2003;56(1):1–9. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors, J Clini Epidemiol. 2003;56(1):1–9.
5.
go back to reference Horne ZD, Jack R, Gray ZT, Landreneau RJ, Siegfried JM, Wilson DO, Schuchert MJ. High levels of tumor-infiltrating lymphocytes and the absence of angiolymphatic invasion increase recurrence-free survival in stage 1A non-small cell lung cancer., J Surg Res. 2011;165(2):189–90. Horne ZD, Jack R, Gray ZT, Landreneau RJ, Siegfried JM, Wilson DO, Schuchert MJ. High levels of tumor-infiltrating lymphocytes and the absence of angiolymphatic invasion increase recurrence-free survival in stage 1A non-small cell lung cancer., J Surg Res. 2011;165(2):189–90.
6.
go back to reference Seyfried F, von Rahden BH, Miras AD, Gasser M, Maeder U, Kunzmann V. Incidence, time course, and independent risk factors for metachronous, BMC Cancer. 2015;15(1):1–10. Seyfried F, von Rahden BH, Miras AD, Gasser M, Maeder U, Kunzmann V. Incidence, time course, and independent risk factors for metachronous, BMC Cancer. 2015;15(1):1–10.
7.
go back to reference Spolverato G, Ejaz A, Kim Y, Squires MH, Poultsides GA, Fields RC, Pawlik T. Rates and patterns of recurrence after curative-intent resection for gastric cancer: J Am Coll Surg. 2014;219(4):164–5. Spolverato G, Ejaz A, Kim Y, Squires MH, Poultsides GA, Fields RC, Pawlik T. Rates and patterns of recurrence after curative-intent resection for gastric cancer: J Am Coll Surg. 2014;219(4):164–5.
8.
go back to reference Chou HH, Kuo CJ, Hsu JT, Chen TH, Lin CJ, Tseng JH, Yeh TS, Hwang TL, Jan YY. Clinicopathologic study of node-negative advanced gastric cancer and analysis of factors predicting its recurrence and prognosis, Am J Surg. 2013;205(6):623–30. Chou HH, Kuo CJ, Hsu JT, Chen TH, Lin CJ, Tseng JH, Yeh TS, Hwang TL, Jan YY. Clinicopathologic study of node-negative advanced gastric cancer and analysis of factors predicting its recurrence and prognosis, Am J Surg. 2013;205(6):623–30.
9.
go back to reference Liu D, Lu M, Li J, Yang Z, Feng Q, Zhou M, Shen L. The patterns and timing of recurrence after curative resection for gastric cancer in China., World J Surg Oncol. 2016;14(1):1–11. Liu D, Lu M, Li J, Yang Z, Feng Q, Zhou M, Shen L. The patterns and timing of recurrence after curative resection for gastric cancer in China., World J Surg Oncol. 2016;14(1):1–11.
10.
go back to reference Lee KW, Bang SM, Kim S, Lee HJ, Shin DY, Koh Y, Lee JS. The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer. , J Thromb Haemos. 20108(3):540–7. Lee KW, Bang SM, Kim S, Lee HJ, Shin DY, Koh Y, Lee JS. The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer. , J Thromb Haemos. 20108(3):540–7.
11.
go back to reference Huang KH, Chen JH, Wu CW, Lo SS, Hsieh MC, Li AFY, Lui WY. Factors affecting recurrence in node‐negative advanced gastric cancer., J Gastroenterol Hepatol. 2009;24(9):1522–6,. Huang KH, Chen JH, Wu CW, Lo SS, Hsieh MC, Li AFY, Lui WY. Factors affecting recurrence in node‐negative advanced gastric cancer., J Gastroenterol Hepatol. 2009;24(9):1522–6,.
12.
go back to reference Mokadem, I, Dijksterhuis WPM, Van Putten M, Heuthorst L, de Vos-Geelen JM. Recurrence after preoperative chemotherapy, Gastric Cancer. 2019;22(6):1263–73. Mokadem, I, Dijksterhuis WPM, Van Putten M, Heuthorst L, de Vos-Geelen JM. Recurrence after preoperative chemotherapy, Gastric Cancer. 2019;22(6):1263–73.
13.
go back to reference Wu J, Liu X, Cai H, Wang Y. Prediction of tumor recurrence after curative resection, World J Surg Oncol. 2014;12(1):1–6. Wu J, Liu X, Cai H, Wang Y. Prediction of tumor recurrence after curative resection, World J Surg Oncol. 2014;12(1):1–6.
14.
go back to reference Lee JH, Kim HI, Kim MG, Ha TK, Jung MS, Kwon SJ. Recurrence of gastric cancer in patients who are disease-free for more than 5 years after primary resection., Surgery. 2016;159(4):190–8. Lee JH, Kim HI, Kim MG, Ha TK, Jung MS, Kwon SJ. Recurrence of gastric cancer in patients who are disease-free for more than 5 years after primary resection., Surgery. 2016;159(4):190–8.
15.
go back to reference Kawamura Y, Satoh S, Umeki Y, Ishida Y, Suda K, Uyama I. Evaluation of the Springer Plus. 2016;5(1):1–9. Kawamura Y, Satoh S, Umeki Y, Ishida Y, Suda K, Uyama I. Evaluation of the Springer Plus. 2016;5(1):1–9.
16.
go back to reference Kang WM, et al. Factors associated with early recurrence after curative surgery for gastric cancer., World J Gastroenterol. 2015. p. 5934. Kang WM, et al. Factors associated with early recurrence after curative surgery for gastric cancer., World J Gastroenterol. 2015. p. 5934.
17.
go back to reference Ha ID, Lee Y. Estimating frailty models via Poisson hierarchical generalized linear models., J Comput Graph Stat. 2003;12.8:663–81. Ha ID, Lee Y. Estimating frailty models via Poisson hierarchical generalized linear models., J Comput Graph Stat. 2003;12.8:663–81.
18.
go back to reference Gomez G, Julià O, Utzet F, Moeschberger ML. Survival analysis for left-censored data., Springer, Dordrecht. 1992. pp. 269–88. Gomez G, Julià O, Utzet F, Moeschberger ML. Survival analysis for left-censored data., Springer, Dordrecht. 1992. pp. 269–88.
19.
go back to reference Duchateau L, Janssen P, Lindsey P, Legrand C, Nguti R, Sylvester R. The shared frailty model and the power for heterogeneity tests in multicenter trials., Comput Stat Data Anal. 2002. pp. 603–20. Duchateau L, Janssen P, Lindsey P, Legrand C, Nguti R, Sylvester R. The shared frailty model and the power for heterogeneity tests in multicenter trials., Comput Stat Data Anal. 2002. pp. 603–20.
20.
go back to reference Kamsali A, Eranti B, Mounika CH, Manne R, Barghav C, Reddy S. Development and optimization of amoxicillin floating raft system to effectively treat Helicobacter pylori infection. Ars Pharmaceutica (Internet). 2020;61(3):163–8.CrossRef Kamsali A, Eranti B, Mounika CH, Manne R, Barghav C, Reddy S. Development and optimization of amoxicillin floating raft system to effectively treat Helicobacter pylori infection. Ars Pharmaceutica (Internet). 2020;61(3):163–8.CrossRef
21.
go back to reference Goethals K, Janssen P, Duchateau L. Frailty models and copulas: similarities and differences., J Appl Stat. 2008. pp. 1071–9. Goethals K, Janssen P, Duchateau L. Frailty models and copulas: similarities and differences., J Appl Stat. 2008. pp. 1071–9.
22.
go back to reference Wienke A, Frailty models in survival analysis., CRC Press. 2010. Wienke A, Frailty models in survival analysis., CRC Press. 2010.
23.
go back to reference Hougaard P. Shared frailty models. Springer, New York, NY: Analysis of multivariate survival data; 2000. p. 215–62. Hougaard P. Shared frailty models. Springer, New York, NY: Analysis of multivariate survival data; 2000. p. 215–62.
24.
go back to reference Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, Gotoda T. Screening for gastric cancer in Asia: current evidence and practice., Lancet Oncol. 2008. pp. 279–87. Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, Gotoda T. Screening for gastric cancer in Asia: current evidence and practice., Lancet Oncol. 2008. pp. 279–87.
25.
go back to reference Yoshida S, Kozu T, Gotoda T, Saito D. Detection and treatment of early cancer in high-risk populations., Best Pract Res Clin Gastroenterol. 2006. pp. 745–65. Yoshida S, Kozu T, Gotoda T, Saito D. Detection and treatment of early cancer in high-risk populations., Best Pract Res Clin Gastroenterol. 2006. pp. 745–65.
26.
go back to reference Shin CH, Lee WY, Hong SW, Chang YG. Characteristics of gastric cancer recurrence five or more years after curative gastrectomy., Chinese J Cancer Res. 2016. p. 503. Shin CH, Lee WY, Hong SW, Chang YG. Characteristics of gastric cancer recurrence five or more years after curative gastrectomy., Chinese J Cancer Res. 2016. p. 503.
27.
go back to reference Jin LX, Moses LE, Squires MH, Poultsides GA, Votanopoulos K, Weber SM, Bloomston M, Pawlik TM, Hawkins WG, Linehan DC, Strasberg SM. Factors associated with recurrence and survival in lymph node–negative gastric adenocarcinoma. Annals Surg. 2015. pp. 999–1005. Jin LX, Moses LE, Squires MH, Poultsides GA, Votanopoulos K, Weber SM, Bloomston M, Pawlik TM, Hawkins WG, Linehan DC, Strasberg SM. Factors associated with recurrence and survival in lymph node–negative gastric adenocarcinoma. Annals Surg. 2015. pp. 999–1005.
28.
go back to reference Cao L, Selby LV, Hu X, Zhang Y, Janjigian YY, Tang L, Coit DG, Brennan MF, Strong VE. Risk factors for recurrence in T1‐2N0 gastric cancer in the United States and China. J Surg Oncol. 2016. pp. 745–49. Cao L, Selby LV, Hu X, Zhang Y, Janjigian YY, Tang L, Coit DG, Brennan MF, Strong VE. Risk factors for recurrence in T1‐2N0 gastric cancer in the United States and China. J Surg Oncol. 2016. pp. 745–49.
29.
go back to reference Kanda M, Mizuno A, Fujii T, Shimoyama Y, Yamada S, Tanaka C, Kobayashi D, Koike M, Iwata N, Niwa Y, Hayashi M. Tumor infiltrative pattern predicts sites of recurrence after curative gastrectomy for stages 2 and 3 gastric cancer., Annals Surg Oncol. 2016;23(6):1934–40. Kanda M, Mizuno A, Fujii T, Shimoyama Y, Yamada S, Tanaka C, Kobayashi D, Koike M, Iwata N, Niwa Y, Hayashi M. Tumor infiltrative pattern predicts sites of recurrence after curative gastrectomy for stages 2 and 3 gastric cancer., Annals Surg Oncol. 2016;23(6):1934–40.
30.
go back to reference Kuo CY, Chao Y, Li CP. Update on treatment of gastric cancer. Kuo, Update on treatment of gastric cancer., J Chinese Med Assoc. 2014;77(7):345–53. Kuo CY, Chao Y, Li CP. Update on treatment of gastric cancer. Kuo, Update on treatment of gastric cancer., J Chinese Med Assoc. 2014;77(7):345–53.
31.
go back to reference Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A, Lieto E. Treatment of gastric cancer., World J Gastroenterol. 2014;WJG 20.7:1635. Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A, Lieto E. Treatment of gastric cancer., World J Gastroenterol. 2014;WJG 20.7:1635.
32.
go back to reference Wu B, Wu D, Wang M, Wang G. Recurrence in patients following curative resection of early gastric carcinoma., J Surg Oncol. 2008. pp. 411–4. Wu B, Wu D, Wang M, Wang G. Recurrence in patients following curative resection of early gastric carcinoma., J Surg Oncol. 2008. pp. 411–4.
33.
go back to reference Liu D, Lu M, Li J, Yang Z, Feng Q, Zhou M, Zhang Z, Shen L. The patterns and timing of recurrence after curative resection for gastric cancer in China., World J Surg Oncol. 2016. pp. 1–11. Liu D, Lu M, Li J, Yang Z, Feng Q, Zhou M, Zhang Z, Shen L. The patterns and timing of recurrence after curative resection for gastric cancer in China., World J Surg Oncol. 2016. pp. 1–11.
34.
go back to reference Smyth EC, Capanu M, Janjigian YY, Kelsen DK, Coit D, Strong VE, Shah MA. Tobacco use is associated with increased recurrence and death from gastric cancer., Ann Surg Oncol. 2012;19(7):2088–94. Smyth EC, Capanu M, Janjigian YY, Kelsen DK, Coit D, Strong VE, Shah MA. Tobacco use is associated with increased recurrence and death from gastric cancer., Ann Surg Oncol. 2012;19(7):2088–94.
35.
go back to reference Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors., J Surg Oncol. 2013;107(3):230–6. Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors., J Surg Oncol. 2013;107(3):230–6.
36.
go back to reference Han MA, Kim YW, Choi IJ, Oh MG, Kim CG, Lee JY, Cho SJ, Eom BW, Yoon HM, Ryu KW. Association of smoking history with cancer recurrence and survival in stage III-IV male gastric cancer patients., Cancer Epidemiol Biomarkers Prev. 2013. pp. 1805–12. Han MA, Kim YW, Choi IJ, Oh MG, Kim CG, Lee JY, Cho SJ, Eom BW, Yoon HM, Ryu KW. Association of smoking history with cancer recurrence and survival in stage III-IV male gastric cancer patients., Cancer Epidemiol Biomarkers Prev. 2013. pp. 1805–12.
37.
go back to reference Shiraishi N, Inomata M, Osawa N, Yasuda K, Adachi Y, Kitano S. Early and late recurrence after gastrectomy for gastric carcinoma: univariate and multivariate analyses., Cancer: Interdiscip Int J Am Cancer Soc. 2000. pp. 255–61. Shiraishi N, Inomata M, Osawa N, Yasuda K, Adachi Y, Kitano S. Early and late recurrence after gastrectomy for gastric carcinoma: univariate and multivariate analyses., Cancer: Interdiscip Int J Am Cancer Soc. 2000. pp. 255–61.
38.
go back to reference Moon YW, Jeung HC, Rha SY, Yoo NC, Roh JK, Noh SH, Kim BS, Chung HC. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single Korean institute., Ann Surg Oncol. 2007. pp. 2730–37. Moon YW, Jeung HC, Rha SY, Yoo NC, Roh JK, Noh SH, Kim BS, Chung HC. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single Korean institute., Ann Surg Oncol. 2007. pp. 2730–37.
39.
go back to reference Cao L, Selby LV, Hu X, Zhang Y, Janjigian YY, Tang L, Coit DG, Brennan MF, Strong VE. Risk factors for recurrence in T1‐2N0 gastric cancer in the United States and China. J Surg Oncol. 2016. pp. 745–9. Cao L, Selby LV, Hu X, Zhang Y, Janjigian YY, Tang L, Coit DG, Brennan MF, Strong VE. Risk factors for recurrence in T1‐2N0 gastric cancer in the United States and China. J Surg Oncol. 2016. pp. 745–9.
40.
go back to reference Shin CH, Lee WY, Hong SW, Chang YG. Characteristics of gastric cancer recurrence five or more years after curative gastrectomy., Chinese J Cancer Res. 2016. p. 503. Shin CH, Lee WY, Hong SW, Chang YG. Characteristics of gastric cancer recurrence five or more years after curative gastrectomy., Chinese J Cancer Res. 2016. p. 503.
41.
go back to reference Corral Cordero F, Cueva Ayala P, Yépez Maldonado J, Tarupi Montenegro W. Trends in cancer incidence and mortality over three decades in Quito-Ecuador., Colombia Médica. 2018. pp. 35–41. Corral Cordero F, Cueva Ayala P, Yépez Maldonado J, Tarupi Montenegro W. Trends in cancer incidence and mortality over three decades in Quito-Ecuador., Colombia Médica. 2018. pp. 35–41.
42.
go back to reference Scheiman JM, Cutler AF. Helicobacter pylori and gastric cancer. Am J Med. 1999;106(2):222–6. Scheiman JM, Cutler AF. Helicobacter pylori and gastric cancer. Am J Med. 1999;106(2):222–6.
43.
go back to reference Matysiak-Budnik T, Mégraud F. Helicobacter pylori infection and gastric cancer. Eur J Cancer. 2006;42(6):708–16. Matysiak-Budnik T, Mégraud F. Helicobacter pylori infection and gastric cancer. Eur J Cancer. 2006;42(6):708–16.
44.
go back to reference Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis., Jama. 2010. pp. 1729–37. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis., Jama. 2010. pp. 1729–37.
45.
go back to reference Abdulkarimova U. Frailty models for modelling heterogeneity, Diss. 2013. Abdulkarimova U. Frailty models for modelling heterogeneity, Diss. 2013.
Metadata
Title
A Case Study on Modeling the Time to Recurrence of Gastric Cancer Patients
Authors
Mesfin Esayas Lelisho
Adem Aregaw Seid
Digvijay Pandey
Publication date
01-03-2022
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 1/2022
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-021-00684-0

Other articles of this Issue 1/2022

Journal of Gastrointestinal Cancer 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine